Skip to main content
. 2011 Dec;22(12):2322–2331. doi: 10.1681/ASN.2010111181

Table 3.

Prevalence rates and age-adjusted and multivariable-adjusted prevalence ratios for anemia, acidosis, hyperphosphatemia, hypoalbuminemia, hyperparathyroidism, and hypertension associated with level of eGFR

eGFR Anemia Acidosis Hyperphosphatemia Hypoalbuminemia Hyperparathyroidism Hypertension
Unadjusted prevalence rates
    ≥120 6.6% 14.5% 8.3% 1.5% 7.1% 7.1%
    90 to 119 4.0% 11.2% 7.2% 1.0% 5.5% 18.3%
    60 to 89 4.7% 8.4% 7.4% 1.3% 9.4% 41.0%
    45 to 59 12.3% 9.4% 9.2% 2.8% 23.0% 71.8%
    30 to 44 22.7% 18.1% 9.3% 9.0% 44.0% 78.3%
    <30 51.5% 31.5% 23.0% 7.5%a 72.5% 82.1%
    P trend <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Age-adjusted prevalence ratios
    ≥120 2.4 (2.0 to 3.0) 1.0 (0.9 to 1.2) 0.9 (0.8 to 1.0) 2.5 (1.7 to 3.8) 1.5 (1.0 to 2.2) 0.8 (0.7 to 0.9)
    90 to 119 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    60 to 89 0.7 (0.6 to 0.9) 1.0 (1.0 to 1.2) 1.3 (1.1 to 1.4) 0.7 (0.5 to 0.9) 1.5 (1.2 to 1.9) 1.1 (1.0 to 1.1)
    45 to 59 1.4 (1.1 to 1.6) 1.4 (1.1 to 1.8) 2.0 (1.7 to 2.4) 0.8 (0.5 to 1.5) 3.2 (2.3 to 4.4) 1.1 (1.1 to 1.1)
    30 to 44 2.3 (1.8 to 2.9) 2.7 (2.2 to 3.4) 2.1 (1.5 to 3.1) 2.5 (1.3 to 4.8) 5.8 (4.2 to 7.9) 1.0 (1.0 to 1.1)
    <30 5.1 (4.1 to 6.5) 4.9 (3.5 to 6.8) 5.1 (3.4 to 7.6) 2.0 (0.9 to 4.7) 9.6 (7.0 to 13.3) 1.1 (0.9 to 1.2)
    P trend <0.001 <0.001 <0.001 0.096 <0.001 <0.001
Adjusted prevalence ratios: model 1b
    ≥120 1.6 (1.3 to 1.9) 0.9 (0.8 to 1.1) 0.9 (0.7 to 1.0) 1.6 (1.1 to 2.3) 1.2 (0.8 to 1.7) 0.7 (0.6 to 0.7)
    90 to 119 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    60 to 89 0.9 (0.7 to 1.0) 1.1 (0.9 to 1.2) 1.3 (1.2 to 1.5) 0.8 (0.6 to 1.1) 1.7 (1.3 to 2.1) 1.1 (1.0 to 1.2)
    45 to 59 1.5 (1.3 to 1.8) 1.4 (1.1 to 1.8) 2.0 (1.7 to 2.4) 0.7 (0.5 to 1.5) 3.4 (2.5 to 4.6) 1.1 (1.0 to 1.1)
    30 to 44 2.4 (1.9 to 3.0) 2.6 (2.1 to 3.3) 2.2 (1.5 to 3.2) 1.9 (1.3 to 3.9) 5.7 (4.3 to 7.6) 1.0 (0.9 to 1.0)
    <30 4.4 (3.4 to 5.8) 4.7 (3.3 to 6.7) 5.33 (3.6 to 7.8) 1.2 (0.5 to 2.8) 8.2 (5.7 to 11.8) 0.8 (0.7 to 1.0)
    P trend <0.001 <0.001 <0.001 0.151 <0.001 0.236
Adjusted prevalence ratios: model 2c
    ≥120 1.5 (1.3 to 1.8) 0.7 (0.9 to 1.1) 0.9 (0.8 to 1.1) 1.6 (1.0 to 2.4) 1.1 (0.8 to 1.7) 0.7 (0.6 to 0.8)
    90 to 119 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    60 to 89 0.9 (0.7 to 1.0) 1.1 (0.9 to 1.2) 1.3 (1.2 to 1.5) 0.9 (0.6 to 1.1) 1.6 (1.2 to 2.0) 1.1 (1.1 to 1.2)
    45 to 59 1.5 (1.3 to 1.8) 1.4 (1.1 to 1.8) 2.1 (1.7 to 2.5) 0.8 (0.5 to 1.4) 3.1 (2.2 to 4.4) 1.0 (1.0 to 1.1)
    30 to 44 2.3 (1.8 to 2.9) 2.8 (2.1 to 3.6) 2.2 (1.5 to 3.3) 1.8 (1.0 to 3.3) 5.0 (3.6 to 6.9) 1.0 (0.9 to 1.0)
    <30 4.2 (3.1 to 5.7) 4.9 (3.4 to 7.1) 4.7 (3.2 to 6.9) 1.3 (0.5 to 3.0) 8.2 (5.7 to 11.5) 0.8 (0.7 to 1.0)
    P trend <0.001 <0.001 <0.001 0.343 <0.001 0.866

All prevalence ratios include adjustment for NHANES phase (1988–1994, 1999–2000, 2001–2002, 2003–2004, or 2005–2006).

aEstimate may be unreliable due to limited number of participants with low serum albumin in this cell.

bThe adjusted prevalence ratio model 1 includes age, race/ethnicity, gender, and log albuminuria.

cThe adjusted prevalence ratio model 2 includes variables in model 1 and cigarette smoking, body mass index, hypertension, diabetes, and C-reactive protein except in the model for hypertension, where hypertension is not adjusted.